Deerfield Management
VC Fund
New York, United States
Deerfield Management is a VC fund in New York focused on Health Care and Biotechnology. Deerfield Management seeks to advance healthcare through investment, information, and philanthropy. The firm was founded in 1994 and is headquartered in New York, New York, United States.
- Total investments:
- 93
- Last investment:
- Lead investor:
- 57%
Last updated:
For AI agents: llms.txt
Industries Deerfield Management invests in
Stages Deerfield Management invests in
Countries Deerfield Management invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jason Fuller
|
|||
|
Michael Foely
|
|||
Michael Foley
|
|||
Steve Anastos
|
|||
Bruce Goldsmith
|
Investment Focus
Industry
- Health Care 55 (59%)
- Biotechnology 53 (57%)
- Medical 30 (32%)
- Therapeutics 20 (22%)
- Pharmaceutical 20 (22%)
Stage
- Series C 18 (19%)
- Series A 16 (17%)
- Series B 16 (17%)
- Post-IPO Debt 13 (14%)
- Post-IPO Equity 10 (11%)
Country
- United States 65 (70%)
- United Kingdom 3 (3%)
- Canada 2 (2%)
- France 2 (2%)
- Israel 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Jason Fuller
Partner
|
Partner | Total investments: 3 | Find email | |
|
Michael Foely
Chief Executive Officer, Deerfield Discovery and Development
|
Chief Executive Officer, Deerfield Discovery and Development | Total investments: 0 | Find email | |
|
Michael Foley
Chief Executive Officer, Deerfield Discovery and Development
|
Chief Executive Officer, Deerfield Discovery and Development | Total investments: 0 | Find email | |
|
Steve Anastos
Principal, Healthcare Services & Technology Investment Team
|
Principal, Healthcare Services & Technology Investment Team | Total investments: 0 | Find email | |
|
Bruce Goldsmith
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Apertura Gene Therapy
|
Apertura Gene Therapy platform leverages ML to engineer novel capsids, gene regulatory elements to simultaneously enhance gene therapies. | $67M / Series A / Apr 26, 2022 | |
Valneva
|
Valneva is a pharmaceutical company developing prophylactic vaccines to treat infectious diseases. The company focused on developing and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs. Valneva has leveraged its expertise and capabilities both to commercialize two vaccines successfully and torapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus, and COVID-19. | $20M / Post-IPO Debt / Apr 26, 2022 | |
Vibliome
|
Vibliome has discovered a new systematic approach that enables the development of small molecule kinase inhibitors with unique selectivity profiles and, in some cases, extraordinary selectivity. There are over 500 kinases in the human genome which control nearly all cellular functions by transferring a polar phosphate group from ATP to regulatoryserine, threonine, or tyrosine residues on proteins. The versatility of our chemistry platform offers many opportunities for variation while maintaining a common general architecture. | $38M / Series A / Feb 24, 2022 | |
Somatus
|
Somatus is a healthcare company that partners with health plans, health systems, and nephrology, and primary care groups. It provides integrated care for patients with or at risk of developing kidney disease. Somatus' is vertically integrated clinical services and technology delay or prevent disease progression, improve quality and carecoordination, and increase the use of home dialysis modalities and rates of kidney transplantation. The company is headquartered in McLean, Virginia, and founded by a team of world-class healthcare operators, successful entrepreneurs, and leading clinicians treating kidney disease. | $325M / Series E / Feb 22, 2022 | |
ConcertoCare
|
ConcertoCare serves patients with Medicare+Medicaid, Medicare Advantage or Medicare, who have complex care needs and an existing primary care provider (PCP). Patients keep their existing doctors and benefit plans. | $105M / Series B / Feb 03, 2022 | |
Hyperfine
|
Hyperfine makes MRI accessible to every patient regardless of income or resources. | $126M / Post-IPO Equity / Dec 23, 2021 | |
The Oncology Institute of Hope and Innovation
|
The Oncology Institute of Hope and Innovation is one of the largest community oncology practices in the U.S. as well as our nation’s leading value-based oncology services platform. The Oncology Institute provides care through more than 80 physicians and advanced practice providers in 50+ clinic locations, with more than 500 total employees helpingto offer leading-edge, evidence-based cancer care to a population of more than 1 million patients. The Oncology Institute brings comprehensive, integrated cancer care into community settings, including clinical trials, stem cell transplants, transfusions, and other care delivery models traditionally associated with the most advanced tertiary care settings. | $275M / Post-IPO Equity / Nov 15, 2021 | |
Lark
|
Lark is a developer of chronic disease prevention and management platform used to prevent chronic conditions. The company uses cutting-edge AI combined with human coaches and connected devices to provide real-time, personalized, 24/7 support, and counseling to help users make healthier choices and manage their conditions. Its CDC-recognizedDiabetes Prevention Program, Wellness Program, Diabetes Care Program, and Hypertension Program have 1.5 million users and have demonstrated clinically validated improved health outcomes published in 11 peer-reviewed journals and analyst reports.Lark was founded by Julia Hu and Jeff Zira in 2011 and is headquartered in Mountain View, California. | $100M / Series D / Oct 13, 2021 | |
DeepSight Technology
|
DeepSight™ Technology is revolutionizing diagnostic medical imaging by taking the safest, fastest, most affordable, and most accessible imaging modality and delivering a quantum leap in performance | $25M / Series A / Oct 11, 2021 | |
BioAtla
|
BioAtla develops safer, more effective drugs for cancer using a proprietary next-generation antibody discovery and evolution platform. BioAtla is a San Diego biotech company that develops novel monoclonal antibody and cell-based therapeutics using our proprietary Conditionally Active Biologics (CAB) and Comprehensive Integrated AntibodyOptimization (CIAO!) platforms. These and other proprietary technologies (protected by more than 150 issued patents and patent applications) allow them to develop novel biologics (CABs) that are better drugs in multiple ways including more selective targeting of cancer tissue and improved manufacturability. Improved selectivity for the tumor microenvironment, even when the target is also found in normal tissue, not only improves safety but also expands the universe of potential drug targets, enabling the treatment of previously untreatable cancers. | $75M / Post-IPO Equity / Sep 29, 2021 | |
| See all 93 investments → | |||
Co-Investors
Deerfield
73 deals together
RA Capital Management
15 deals together
Logos Capital
10 deals together
OrbiMed
10 deals together
Perceptive Advisors
9 deals together
Janus Henderson Investors
7 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Deerfield Management invest in?
Deerfield Management invests primarily in Health Care, Biotechnology and Medical startups, most often at Series C and Series A stage. Most of the 93 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Deerfield Management?
Public channels for Deerfield Management include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Deerfield Management?
The team at Deerfield Management includes Jason Fuller (Partner), Michael Foely (Chief Executive Officer, Deerfield Discovery and Development) and Michael Foley (Chief Executive Officer, Deerfield Discovery and Development), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
